March 12, 2024, Imaging Biometrics, LLC (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCBB: IQAIF), is pleased to announce the results of a study published in the American Journal of Neuroradiology (AJNR). The study, Arterial Spin-Labeling and DSC Perfusion Metrics Improve Agreement in Neuroradiologists’ Clinical Interpretations of Posttreatment High-Grade Glioma Surveillance MR Imaging—An Institutional Experience, was led by Dr. Michael Iv, MD, Associate Professor and Director of Brain Tumor Imaging at Stanford University Medical Center.

While the study demonstrated that, in general, perfusion improved interreader agreement and confidence in neuroradiologist interpretation, IB’s DSC-FTB resulted in the highest agreement in BT-RADS (a structured reporting system specific to brain tumors) scores among all raters as well as the highest confidence scores for interpretation. Moreover, perfusion MRI resulted in interpretation changes that could alter therapeutic management in up to 20% of patients.

IB’s FTB maps are generated from IB Delta T1 and IB Neuro’s standardized relative cerebral blood volume (sRCBV) maps; both of which are quantitative. “The quantitative characteristics of these maps is a key differentiator as it enables consistent and accurate output independent of scanner vendor, field strength, patient, or time point,” said Michael Schmainda, CEO of IB. The quantitative maps also allow for direct volumetric comparison across time to monitor response to treatment.
As the paper noted, the high-level of agreement was found despite the range of practice experience suggesting that IB’s DSC-FTB maps seem to level the playing ground for interpretation based on experience.


About Imaging Biometrics® LLC:
IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively.

MRI Homepage